Sobi North America Leadership Team
Sobi North America Leadership Team
Duane H. Barnes – President, Sobi North America
Employed since January 2021. MBA and MSc from Indiana University – Kelley School of Business, B.A. degree from West Virginia University. More than 30 years of experience spanning large pharma, biotech, payor and pharmacy in key executive and business development roles.
Most recently President and Head of U.S. Operations at UCB BioPharma where he oversaw Government Affairs, Policy, Advocacy, Communications, Market Access, Contracting & Pricing, Payer Strategy, Operations Excellence and chaired the U.S. Leadership Team. Previous positions included executive roles at Amgen, Prime Therapeutics, Aetna, Medco Health Solutions, Merck-Medco and Quest Diagnostics.
Joel Batten – Vice President, Franchise Head of Synagis® (palivizumab) Franchise, North America
Employed since January 2019. More than 20 years of experience in the pharmaceutical industry spanning sales, marketing, market access, government affairs and public health.
Previous positions: Multiple leadership positions at Medimmune, AstraZeneca and Sobi from 2006-2019, most recently Executive Business Director over the Synagis sales organization. Additional roles included Commercial Business Director for the Respiratory Franchise, Regional Director of the Public Health division and lead for the State Government Affairs team.
Christine Belin – Chief Financial Officer, North America
Employed since September 2014. MBA - Johnson Graduate School of Management at Cornell University, BS in Chemical Engineering from Cornell University. Over 15 years of experience in the pharmaceutical industry in a variety of finance leadership roles.
Previous positions: Director of Finance and Revenue Accounting at ARIAD Pharmaceuticals 2013-2014, Director of Commercial Financial Planning and Analysis at Human Genome Sciences 2010-2013 and various positions at Amgen from 2002 through 2010 including Director of Finance for Colorado Operations 2007-2010 and Senior Finance Manager of Europe R&D at Amgen, Ltd in Cambridge, UK 2005-2007. Before Amgen, she worked as a reservoir engineer at Shell Exploration and Production Co.
Geoff Ebeling – Vice President, Strategy & Business Optimization, North America
Employed since June 2019. MBA – Harvard University, B.S. in Mechanical Engineering from the Massachusetts Institute of Technology. Significant pharmaceutical and biotech experience spanning program management, strategic planning, M&A and operational improvement.
Previous positions: Vice President, Corporate Integration and M&A Strategic Programs Lead at Shire. Principal at Bain & Company, providing corporate and commercial strategy consultation and performance improvement to clients across healthcare and life sciences.
Heather Golding - General Counsel, North America
Employed since November 2015. J.D. - University of Connecticut School of Law. B.A. - International Studies, Colby College. Over 10 years of experience providing legal and compliance guidance to the pharmaceutical industry.
Previous positions: Director, Legal and Compliance at Takeda Oncology, formerly Millennium Pharmaceuticals (2011-2013); Assoc. Director, Corporate Compliance at Takeda Oncology (2011-2013). Associate, Government Enforcement and Compliance Practice Group at Choate, Hall & Stewart LLP (2005-2011). Special Assistant District Attorney, Suffolk County, MA (2010).
Bob Jahr– Chief Commercial Officer, Sobi North America
Bob joined Sobi North America as Chief Commercial Officer in May, 2021. In this role, he is responsible for overseeing and accelerating the North America commercial strategy as well as planning and executional excellence. He is accountable for all marketing, sales, operations and market access activities with a focus on driving and accelerate business growth in North America, ensuring an integrated commercial strategy and delivering optimal operational execution.
Bob has more than 20 years experience in the biopharmaceutical industry and has a deep understanding across therapeutic markets and geographies. He joins Sobi NA from UCB, where he served as Head of International Markets leading global teams including China, Japan, and Canada, and before that e held leadership roles in sales, marketing, operations, payor strategy and market access at Amgen and Regeneron.
Bob received a Bachelor of Science and an MBA from the University of Montana.
Doug Kylander - Head of Market Access and Government Affairs (Interim) | Vice President, Market Access and Patient Services
Employed since April 2019. MBA, University of Michigan – Stephen M. Ross School of Business, B.A. degree from Dartmouth College. More than 20 years market access and government affairs experience in pharmaceuticals and healthcare industry.
Mostly recently Head of Market Access, Pharmacyclics. Previous positions included senior leadership roles at Incyte, Janssen and Ortho Therapeutic. He has supported commercial and new product development globally for hematology and oncology products.
Bob McLay – General Manager, Canada and Vice President, Franchise Head of Kineret® (anakinra) and Orfadin® (nitisinone) in North America
Employed since February 2016. MBA - Auburn University, Auburn Alabama. Bsc - University of Guelph, Guelph, Ontario. Over 23 years of experience in the pharmaceutical industry with multiple leadership roles in marketing, sales, patient access, supply chain, trade relations and business development.
Previous positions: Multiple senior level positions with both large and small pharmaceutical companies. Most recently, VP Sales and Marketing & Canadian Commercial Lead at Merus Labs International (2014-2015), Director of Sales at Takeda Canada (2012-2013), Marketing Director at Graceway Pharmaceuticals (2007-2012), Associate Sales Director and other various sales and marketing roles at Pfizer Canada (1994-2007)
Joshua Prabhakar – Vice President, Head of Doptelet Franchise North America
Joshua serves as Vice President, Head of Doptelet® Franchise for Sobi North America. In this role, he is responsible for all commercial activities for the Doptelet franchise in North America, strategy and all marketing and sales activities.
Joshua has more than 20 years’ experience in the biopharmaceutical and pharmaceutical industries, most recently serving as Vice President Marketing at Dova Pharmaceuticals, now Sobi NA. While in this role, he led a third-to-market product that exceeded expectations. His experience also includes marketing and sales roles at Alder Biopharmaceuticals and GlaxoSmithKline. During his tenure with GSK, he was involved in the launch of six products, in addition to managing other assets through various phases of the commercial lifecycle.
He earned a Master of Science degree in Molecular Genetics from Purdue University and a Bachelor of Specialized Science degree in Biology from Huntington University. He is based in Durham, NC.
Stephen Smolinski - Vice President, Head of U.S. Gamifant® and Global Immunology Strategic Marketing
Employed since September 2020. Significant experience in pharmaceutical and biotech industry, spanning business development, commercialization and marketing strategy.
Previous positions: Most recently Chief Commercial Officer for Selecta Biosciences (2017-2020). Additional roles include Vice President and Head of Sanofi/Genzyme’s North American Rheumatology Business Unit, Group Vice President of Immunology & Inflammation - Global Strategic Unit at Sanofi and multiple senior commercial roles at Roche-Genetech, Bristol-Myers Squibb, Johnson & Johnson and Savient Pharmaceuticals.
Megan Sullivan – Vice President, Head of Commercial Innovation, North America
Employed since September 2019. B.S. from Loyola University of Chicago. Over 20 years experience in pharmaceutical, biotech and the medical device industry in various commercial roles spanning sales, sales leadership, training, analytics, commercial effectiveness and commercial operations.
Previous positions: Multiple leadership positions within Shire since 2016, most recently as Vice President, U.S. Commercial Operations (2018-2019). Senior Director, Commercial Leadership Development, Sales Training & Meetings at Lundbeck (2012-2016). Various sales, sales leadership and operational roles at Baxter Healthcare (2010-2012), Boston Scientific (2007-2010), LMA North America (2006-2007) and Janssen Pharmaceuticals (1998-2006).
Jim Trimble - Head of Human Resources, Ad Interim
Employed since January 2020. B.A. degree from the University of Akron. More than 20 years Human Resource experience, including 10 years within healthcare including roles in HR leadership, talent acquisition and talent management.
Mostly recently Vice President, Human Resources for North America, BSN Medical where he led a team of HR business partners in support of ~700 employees across the country. Previous positions included HR leadership roles at Leggett & Platt and CompuCom.
John Yee, MD, MPH – Chief Medical Officer, North America
Employed since April 2020. A.B. in History and Science from Harvard College; M.D. from Harvard Medical School; M.P.H. from the Harvard T.H. Chan School of Public Health. Over 20 years of progressive leadership experience in academia and industry, with experience leading the launch of multiple new drugs across therapeutic areas in orphan, ultra-orphan and more prevalent diseases.
Previous positions: Multiple leadership positions within Genzyme (2003-2011), AstraZeneca (2011-2016), Intarcia Therapeutics (2016-2017), Vertex Pharmaceuticals (2017-2019) and Flexion Therapeutics. Completed a residency in pediatrics and fellowships in immunology/rheumatology and health services research at Boston Children’s Hospital and served on the faculty at Boston Children’s Hospital and Harvard Medical School prior to industry leadership roles.